NCT04264260View on ClinicalTrials.gov

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 24, 2019

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Hepatocellular Carcinoma Stage IIIBCholangiocarcinoma, IntrahepaticCholangiocarcinoma; With Hepatocellular CarcinomaHepatocellular Carcinoma Stage IV
Interventions
DRUG

Colchicine Tablets

three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
collaborator

Kaohsiung Medical University

OTHER

lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT04264260 - Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment | Biotech Hunter | Biotech Hunter